AbCellera Biologics Inc. | Small-cap | Healthcare
$3.49
1.75%
| AbCellera Biologics Stock Comparison:
AbCellera Biologics vs VertexAbCellera Biologics vs RegeneronAbCellera Biologics vs Vera TherapeuticsAbCellera Biologics vs Immunocore HoldingsAbCellera Biologics vs AgiosAbCellera Biologics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 28.8M
Gross Profit 28.8M 100.00%
Operating Income -301.1M -1,044.45%
Net Income -162.9M -564.83%
EPS (Diluted) -$0.55

Balance Sheet Metrics

Total Assets 1.4B
Total Liabilities 304.5M
Shareholders Equity 1.1B
Debt to Equity 0.29

Cash Flow Metrics

Operating Cash Flow -119.2M
Free Cash Flow -187.0M

Revenue & Profitability Trend

AbCellera Biologics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 28.8M 38.0M 485.4M 375.2M 233.2M
Cost of Goods Sold 0 0 66.4M 45.5M 27.1M
Gross Profit 28.8M 38.0M 419.0M 329.7M 206.0M
Operating Expenses 239.1M 236.7M 164.1M 93.3M 36.8M
Operating Income -301.1M -223.1M 227.1M 221.9M 164.4M
Pre-tax Income -200.4M -174.0M 239.1M 219.1M 157.8M
Income Tax -37.5M -27.6M 80.6M 65.7M 38.9M
Net Income -162.9M -146.4M 158.5M 153.5M 118.9M
EPS (Diluted) -$0.55 -$0.51 $0.50 $0.48 $0.45

Income Statement Trend

AbCellera Biologics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 751.4M 872.0M 1.0B 929.8M 813.3M
Non-Current Assets 609.2M 616.1M 515.4M 388.8M 192.2M
Total Assets 1.4B 1.5B 1.5B 1.3B 1.0B
Liabilities
Current Liabilities 76.6M 119.0M 118.3M 120.7M 103.5M
Non-Current Liabilities 227.9M 216.8M 189.3M 172.2M 71.5M
Total Liabilities 304.5M 335.8M 307.6M 292.8M 175.0M
Equity
Total Shareholders Equity 1.1B 1.2B 1.2B 1.0B 830.5M

Balance Sheet Composition

AbCellera Biologics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -162.9M -146.4M 158.5M 153.5M 118.9M
Operating Cash Flow -119.2M -43.9M 274.3M 243.8M -40.9M
Investing Activities
Capital Expenditures -78.4M -76.9M -70.7M -58.5M -9.7M
Investing Cash Flow 121.4M -220.5M -350.6M -332.2M -114.8M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 12.8M 10.4M -2.0M -5.7M 682.7M
Free Cash Flow -187.0M -121.4M 204.7M 186.1M 8.0M

Cash Flow Trend

AbCellera Biologics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -6.05
Forward P/E -5.05
Price to Book 0.97
Price to Sales 43.00
PEG Ratio -5.05

Profitability Ratios

Profit Margin 100.00%
Operating Margin -1,479.58%
Return on Equity -15.60%
Return on Assets -12.94%

Financial Health

Current Ratio 10.15
Debt to Equity 6.63
Beta 0.36

Per Share Data

EPS (TTM) -$0.56
Book Value per Share $3.43
Revenue per Share $0.08

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
abcl 994.0M -6.05 0.97 -15.60% 100.00% 6.63
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Vera Therapeutics 1.4B -8.41 2.58 -39.49% 0.00% 10.18
Immunocore Holdings 1.6B -31.41 4.13 -5.86% -6.48% 114.67
Agios 1.9B 2.89 1.32 60.26% 1,798.26% 3.61

Financial data is updated regularly. All figures are in the company's reporting currency.